Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing patients with Crohn’s disease and ulcerative colitis into unnecessary administrative battles and suboptimal treatment pathways.

Hospitals Defy National Ordinance

Selected public facilities, including Hospital Beatriz Ângelo and Hospital Garcia de Orta, systematically refuse to dispense reimbursed biologic drugs when the prescription originates outside their own departments. This occurs even when patients were previously followed at these same centres and despite the explicit provisions of Portaria n.º 261/2024, which extended private prescribing rights precisely to eliminate such disparities.

Patients Forced to Prove the Law

In documented cases, individuals delayed by long hospital waiting lists sought private consultations only to have their prescriptions rejected at the pharmacy counter. Some were told the hospital “does not accept external prescriptions,” while others had to return with printed copies of the decree because staff claimed unfamiliarity or outright disagreement with the regulation. The president of the Portuguese Society of Gastroenterology has personally intervened in several episodes to enforce compliance.

Daily Life Disrupted by Subcutaneous Restrictions

Certain hospitals further compound the problem by withholding subcutaneous formulations of these biologics, compelling working-age patients to make repeated visits for intravenous infusions. The resulting loss of productivity and increased burden on chronically ill individuals illustrates how biologic dispensing implementation gaps translate directly into poorer quality of life and inefficient use of healthcare resources.

Enforcement Must Match Legislative Intent

These persistent biologic dispensing implementation gaps demonstrate that regulatory reform alone cannot guarantee access without robust monitoring, staff training, and clear accountability mechanisms. Until hospitals are compelled to align dispensing protocols with the updated law, patients with inflammatory bowel disease will continue to face unequal treatment despite national policy designed to protect them.